Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 590
Gene Symbol: BCHE
BCHE
CUI: C0026896
Disease: Myasthenia Gravis
Myasthenia Gravis
0.100 Biomarker BEFREE Distigmine bromide (distigmine) is a reversible carbamate cholinesterase (ChE) inhibitor that is used to treat myasthenia gravis. 31614352

2020

Entrez Id: 590
Gene Symbol: BCHE
BCHE
CUI: C0026896
Disease: Myasthenia Gravis
Myasthenia Gravis
0.100 Biomarker BEFREE Subsequently, acetyl cholinesterase antibodies were checked which came out positive, and diagnosis of myasthenia gravis and hypokalemic periodic paralysis was made. 31586958

2019

Entrez Id: 590
Gene Symbol: BCHE
BCHE
CUI: C0026896
Disease: Myasthenia Gravis
Myasthenia Gravis
0.100 Biomarker BEFREE Most notably, cholinesterase inhibitors are used to alleviate the symptoms of neurological disorders like dementia and Alzheimer's disease and treat myasthenia gravis and glaucoma. 30924818

2019

Entrez Id: 590
Gene Symbol: BCHE
BCHE
CUI: C0026896
Disease: Myasthenia Gravis
Myasthenia Gravis
0.100 Biomarker BEFREE Cholinesterase inhibitors (e.g., pyridostigmine bromide), glucocorticoids, and azathioprine are currently recommended as first-line treatments for MG, though they have limitations, including potential toxicity and ineffectiveness in patients with refractory MG. 31393614

2019

Entrez Id: 590
Gene Symbol: BCHE
BCHE
CUI: C0026896
Disease: Myasthenia Gravis
Myasthenia Gravis
0.100 Biomarker BEFREE Two patients presented with SLE who have been effectively treated with cholinesterase inhibitors for MG. 30025818

2018

Entrez Id: 590
Gene Symbol: BCHE
BCHE
CUI: C0026896
Disease: Myasthenia Gravis
Myasthenia Gravis
0.100 AlteredExpression BEFREE Both quaternization upon methylation of the quinoline nitrogen atom, and tethering of a triazole ring, with, in some cases, the additional incorporation of a polyphenol-like moiety, result in more polar compounds with higher inhibitory activity against human AChE (up to 190-fold) and butyrylcholinesterase (up to 40-fold) than pyridostigmine, the standard drug for symptomatic treatment of myasthenia gravis. 29534488

2018

Entrez Id: 590
Gene Symbol: BCHE
BCHE
CUI: C0026896
Disease: Myasthenia Gravis
Myasthenia Gravis
0.100 Biomarker BEFREE Treatment of Myasthenia Gravis With High-Dose Cholinesterase Inhibitors and Calcineurin Inhibitors Caused Spontaneous Muscle Cramps in Patients. 30130259

2018

Entrez Id: 590
Gene Symbol: BCHE
BCHE
CUI: C0026896
Disease: Myasthenia Gravis
Myasthenia Gravis
0.100 Biomarker BEFREE Thus, compared to other cholinesterase inhibitors used for palliative treatment of myasthenia gravis, C-547 is the most selective drug, displays a slow pharmacokinetics, and has the longest duration of action. 29277489

2018

Entrez Id: 590
Gene Symbol: BCHE
BCHE
CUI: C0026896
Disease: Myasthenia Gravis
Myasthenia Gravis
0.100 Biomarker BEFREE MuSK antibody-positive myasthenia gravis (MG) accounts for 5-15% of autoimmune MG. As AChR deficiency is typically mild and as cholinesterase inhibitors are generally ineffective or worsen myasthenic symptoms, we asked if the patient's MuSK-IgG interferes with binding of ColQ to MuSK. 22981737

2013

Entrez Id: 590
Gene Symbol: BCHE
BCHE
CUI: C0026896
Disease: Myasthenia Gravis
Myasthenia Gravis
0.100 Biomarker BEFREE Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment. 21397501

2011